ATE333901T1 - Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin - Google Patents

Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin

Info

Publication number
ATE333901T1
ATE333901T1 AT01990621T AT01990621T ATE333901T1 AT E333901 T1 ATE333901 T1 AT E333901T1 AT 01990621 T AT01990621 T AT 01990621T AT 01990621 T AT01990621 T AT 01990621T AT E333901 T1 ATE333901 T1 AT E333901T1
Authority
AT
Austria
Prior art keywords
biguanine
metformin
arginine
pharmaceutical composition
diabetes
Prior art date
Application number
AT01990621T
Other languages
English (en)
Inventor
Jean-Robert Rapin
Dominique Halbitte
Original Assignee
Dospharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dospharma filed Critical Dospharma
Application granted granted Critical
Publication of ATE333901T1 publication Critical patent/ATE333901T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01990621T 2000-12-29 2001-12-31 Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin ATE333901T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0017332A FR2818906B1 (fr) 2000-12-29 2000-12-29 Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine

Publications (1)

Publication Number Publication Date
ATE333901T1 true ATE333901T1 (de) 2006-08-15

Family

ID=8858430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01990621T ATE333901T1 (de) 2000-12-29 2001-12-31 Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin

Country Status (15)

Country Link
US (2) US7265156B2 (de)
EP (1) EP1349578B1 (de)
JP (1) JP4477301B2 (de)
AT (1) ATE333901T1 (de)
CA (1) CA2435484A1 (de)
CY (1) CY1105736T1 (de)
DE (1) DE60121804T2 (de)
DK (1) DK1349578T3 (de)
ES (1) ES2271103T3 (de)
FR (1) FR2818906B1 (de)
NZ (1) NZ527206A (de)
PT (1) PT1349578E (de)
RU (1) RU2003123491A (de)
WO (1) WO2002053090A2 (de)
ZA (1) ZA200207761B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CN101437823B (zh) 2006-05-04 2014-12-10 勃林格殷格翰国际有限公司 多晶型
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
MX370429B (es) 2009-10-02 2019-12-13 Boehringer Ingelheim Int Gmbh Star Composiciones farmacéuticas que comprenden bi-1356 y metformina.
WO2011051974A1 (en) * 2009-10-29 2011-05-05 Nutracryst Therapeutics Private Limited Metformin and a-amino acids
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US20120178813A1 (en) * 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
EP2849755A1 (de) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH Xanthinderivat als dpp-4-hemmer zur verwendung bei der behandlung von durch podozyten vermittelten erkrankungen und/oder des nephrotischen syndroms
CN105277705A (zh) * 2014-07-24 2016-01-27 江苏维赛科技生物发展有限公司 一种检测双胍类药物残留的试剂盒的制备及其检测方法
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2037002A1 (en) * 1969-04-30 1970-12-31 Roques Bernard N-substd biguanide pamoic acid salts prepn
FR2696740B1 (fr) * 1992-10-13 1994-12-30 Dospharma Sa Dérivés prodrogués de la diméthylbiguanide et applications comme médicaments.
WO1999029314A1 (en) * 1997-12-08 1999-06-17 Bristol-Myers Squibb Company Novel salts of metformin and method
KR100620935B1 (ko) * 1998-03-19 2006-09-13 브리스톨-마이어스스퀴브컴파니 용해도가 높은 약물에 대한 2상 서방성 전달 시스템과 방법
DE69918105T2 (de) * 1998-04-29 2005-07-07 Sumitomo Pharmaceuticals Co., Ltd. Orale zubereitung enthaltend einen biguanid und eine organische säure
FR2796551B1 (fr) * 1999-07-23 2003-07-25 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
WO2002012177A1 (en) * 2000-08-03 2002-02-14 Igor Anatolievich Pomytkin Composition of metformin with succinic acid or salts thereof and method for treating diabetes

Also Published As

Publication number Publication date
WO2002053090A2 (fr) 2002-07-11
CY1105736T1 (el) 2010-12-22
DE60121804T2 (de) 2007-08-23
NZ527206A (en) 2006-12-22
US7265156B2 (en) 2007-09-04
FR2818906A1 (fr) 2002-07-05
EP1349578A2 (de) 2003-10-08
PT1349578E (pt) 2006-12-29
US20070265349A1 (en) 2007-11-15
JP4477301B2 (ja) 2010-06-09
DK1349578T3 (da) 2006-11-27
RU2003123491A (ru) 2005-01-10
FR2818906B1 (fr) 2004-04-02
DE60121804D1 (de) 2006-09-07
ES2271103T3 (es) 2007-04-16
JP2004517105A (ja) 2004-06-10
CA2435484A1 (fr) 2002-07-11
WO2002053090A3 (fr) 2003-02-20
ZA200207761B (en) 2004-05-28
EP1349578B1 (de) 2006-07-26
US20040097399A1 (en) 2004-05-20

Similar Documents

Publication Publication Date Title
SE0001899D0 (sv) New compounds
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
DE60121804D1 (de) Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
IS6614A (is) Ný tríasólpýrimídínefnasambönd
CY1111543T1 (el) Νεες ενωσεις
MX2007006397A (es) Derivados de tetrahidropirano.
SE9904505D0 (sv) Novel compounds
RS51444B (sr) JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa
RS93604A (en) Substituted phenylacetamides and their use as glucokinase activators
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
EA200400432A1 (ru) Производные мочевины
EA200300323A1 (ru) ПРОИЗВОДНЫЕ ГУАНИДИНОБЕНЗАМИДА (ВАРИАНТЫ), КОМПОЗИЦИЯ (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ ОПОСРЕДОВАННОГО mc4-r ЗАБОЛЕВАНИЯ (ВАРИАНТЫ)
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
SE0100901D0 (sv) New composition
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
TR200401029T4 (tr) Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
SE0102438D0 (sv) New compounds
GT200000103A (es) Trifluorbutenos nematocidas.
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
YU87202A (sh) Derivati arilmetilamina koji se koriste kao inhibitori triptaze
DE60336225D1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
MY134026A (en) ?-carboline derivatives and its pharmaceutical use against depression and anxiety

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1349578

Country of ref document: EP

EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee